BriaCell Secures $2.05 Million NCI Grant to Advance Bria-PROS+™ Immunotherapy in Metastatic Prostate Cancer

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a ...

August 25, 2025 | Monday | News
Innovent Biologics Receives FDA Clearance to Launch First Global Phase 3 Trial of IBI363 in IO-Resistant Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing h...

August 25, 2025 | Monday | News
BlossomHill Therapeutics Doses First Patient in SOLARA Trial Expansion of First-in-Class OMNI-EGFR™ Inhibitor

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines ...

August 25, 2025 | Monday | News
PathAI and Moffitt Cancer Center Launch Strategic Collaboration to Shape the Future of Cancer Care

PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation’s top cancer hospi...

August 22, 2025 | Friday | News
InnoCare Pharma Begins Registrational Study of Mesutoclax in China, Offering New Hope for Lymphoma Patients Globally

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has...

August 22, 2025 | Friday | News
Agilent MMR IHC Panel pharmDx Wins FDA Approval as Companion Diagnostic for Colorectal Cancer

-Agilent Technologies Inc. announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for ...

August 21, 2025 | Thursday | News
Idorsia’s TRYVIO™ Included in New ACC/AHA Hypertension Guidelines as a Novel Treatment Option

Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new co...

August 20, 2025 | Wednesday | News
Trethera Secures $3 Million NIH Grant to Advance TRE-515 for Lupus Treatment

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

August 20, 2025 | Wednesday | News
RemeGen and Santen Forge Strategic Alliance to Advance RC28-E for Retinal Diseases Across Asia

RemeGen Co., Ltd, a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) C...

August 19, 2025 | Tuesday | News
Regen BioPharma Advances HemaXellerate Toward Phase 1 Trials Following FDA Clearance

Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company&...

August 18, 2025 | Monday | News
Ascentage Pharma Receives FDA and EMA Clearance for Global Phase III Trial of Lisaftoclax in Higher-Risk MDS

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and c...

August 18, 2025 | Monday | News
Insmed Secures FDA Approval for BRINSUPRI™, the First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung D...

August 14, 2025 | Thursday | News
MAIA Biotechnology Secures European Patent for Next-Generation Telomere-Targeting Cancer Therapies

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...

August 14, 2025 | Thursday | News
Bayer and Kumquat Biosciences Partner to Develop First-in-Class KRAS G12D Inhibitor for Hard-to-Treat Cancers

Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancr...

August 13, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close